These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 23924450

  • 21. Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma.
    Nagyiványi K, Budai B, Bíró K, Gyergyay F, Noszek L, Küronya Z, Németh H, Nagy P, Géczi L.
    Clin Genitourin Cancer; 2016 Aug; 14(4):314-22. PubMed ID: 26774206
    [Abstract] [Full Text] [Related]

  • 22. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.
    Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC, Campbell SC.
    J Urol; 2009 Feb; 181(2):518-23; discussion 523. PubMed ID: 19100579
    [Abstract] [Full Text] [Related]

  • 23. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ, Lee JL, Park I, Park K, Ahn Y, Ahn JH, Lee DH, Ahn S, Song C, Hong JH, Kim CS, Ahn H.
    Chemotherapy; 2012 Feb; 58(6):468-74. PubMed ID: 23548259
    [Abstract] [Full Text] [Related]

  • 24. Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma.
    Iwamoto K, Ishihara H, Takagi T, Kondo T, Yoshida K, Iizuka J, Tanabe K.
    Med Oncol; 2018 Apr 23; 35(6):78. PubMed ID: 29687160
    [Abstract] [Full Text] [Related]

  • 25. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
    Paglino C, Imarisio I, Ganini C, Morbini P, Vercelli A, Bregant C, Porta C.
    Future Oncol; 2012 Dec 23; 8(12):1605-12. PubMed ID: 23231522
    [Abstract] [Full Text] [Related]

  • 26. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
    Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ.
    J Clin Oncol; 2017 Feb 20; 35(6):591-597. PubMed ID: 28199818
    [Abstract] [Full Text] [Related]

  • 27. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
    Najjar YG, Mittal K, Elson P, Wood L, Garcia JA, Dreicer R, Rini BI.
    Eur J Cancer; 2014 Apr 20; 50(6):1084-9. PubMed ID: 24559686
    [Abstract] [Full Text] [Related]

  • 28. Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.
    Atkins MB, Gravis G, Drosik K, Demkow T, Tomczak P, Wong SS, Michaelson MD, Choueiri TK, Wu B, Navale L, Warner D, Ravaud A.
    J Clin Oncol; 2015 Oct 20; 33(30):3431-8. PubMed ID: 26304872
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: Comparison with standard 4/2 schedule.
    Ohba K, Miyata Y, Yasuda T, Asai A, Mitsunari K, Matsuo T, Mochizuki Y, Matsunaga N, Sakai H.
    Asia Pac J Clin Oncol; 2018 Jun 20; 14(3):153-158. PubMed ID: 29383843
    [Abstract] [Full Text] [Related]

  • 30. Central and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial.
    Vrdoljak E, Géczi L, Mardiak J, Ciuleanu TE, Leyman S, Zhang K, Sajben P, Torday L.
    Pathol Oncol Res; 2015 Jul 20; 21(3):775-82. PubMed ID: 25557271
    [Abstract] [Full Text] [Related]

  • 31. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
    Kondo T, Takagi T, Kobayashi H, Iizuka J, Nozaki T, Hashimoto Y, Ikezawa E, Yoshida K, Omae K, Tanabe K.
    Jpn J Clin Oncol; 2014 Mar 20; 44(3):270-7. PubMed ID: 24474815
    [Abstract] [Full Text] [Related]

  • 32. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Johannsen M, Flörcken A, Bex A, Roigas J, Cosentino M, Ficarra V, Kloeters C, Rief M, Rogalla P, Miller K, Grünwald V.
    Eur Urol; 2009 Jun 20; 55(6):1430-8. PubMed ID: 18950936
    [Abstract] [Full Text] [Related]

  • 33. Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
    Kruse V, Somers A, Van Bortel L, De Both A, Van Belle S, Rottey S.
    J Clin Pharm Ther; 2014 Jun 20; 39(3):259-65. PubMed ID: 24417304
    [Abstract] [Full Text] [Related]

  • 34. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
    Rini BI, Stein M, Shannon P, Eddy S, Tyler A, Stephenson JJ, Catlett L, Huang B, Healey D, Gordon M.
    Cancer; 2011 Feb 15; 117(4):758-67. PubMed ID: 20922784
    [Abstract] [Full Text] [Related]

  • 35. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.
    Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Hawkins RE, Crinò L, Kim TM, Carteni G, Eberhardt WE, Zhang K, Fly K, Matczak E, Lechuga MJ, Hariharan S, Bukowski R.
    Br J Cancer; 2015 Jun 30; 113(1):12-9. PubMed ID: 26086878
    [Abstract] [Full Text] [Related]

  • 36. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib.
    Miyake H, Harada K, Miyazaki A, Fujisawa M.
    Med Oncol; 2015 Mar 30; 32(3):78. PubMed ID: 25698532
    [Abstract] [Full Text] [Related]

  • 37. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ.
    J Clin Oncol; 2008 Aug 01; 26(22):3743-8. PubMed ID: 18669461
    [Abstract] [Full Text] [Related]

  • 38. A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis.
    Buti S, Donini M, Lazzarelli S, Passalacqua R.
    Acta Biomed; 2012 Aug 01; 83(2):88-94. PubMed ID: 23393915
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
    Kim KH, Kim HY, Kim HR, Sun JM, Lim HY, Lee HJ, Lee S, Bae WK, Rha SY, Korean Cancer Study Group, Genitourinary & Gynecology Cancer Committee.
    Eur J Cancer; 2014 Mar 01; 50(4):746-52. PubMed ID: 24332573
    [Abstract] [Full Text] [Related]

  • 40. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.
    Castellano D, Maroto JP, Espinosa E, Grande E, Bolós MV, Llinares J, Esteban E, González Del Alba A, Climent MA, Arranz JA, Méndez MJ, Fernández Parra E, Antón-Aparicio L, Bayona C, Gallegos I, Gallardo E, Samaniego L, García Donas J.
    Expert Opin Drug Saf; 2018 Jun 01; 17(6):573-579. PubMed ID: 28535693
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.